Thomson Reuters Creates The Outpartnering Registry, a Free Resource to
Improve Drug Development Partnering

    


    
</pre>
<p><span class="xn-location">PHILADELPHIA</span> and <span class="xn-location">LONDON</span>, <span class="xn-chron">June 21</span> /CNW/ -- Thomson Reuters announced today that it has launched The Outpartnering Registry, an innovative resource designed to change the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around the world.</p>
<p/>
<p>The Outpartnering Registry is available free to all organizations with drugs in development. It enables authorized users to share essential information about their company and drug pipeline with potential partners. Ninety percent of the world's top 50 pharmaceutical companies will have access to information in the registry via Thomson Pharma® Partnering, the leading source of pipeline intelligence.</p>
<pre>
    

    The Outpartnering Registry allows organizations to:
    --  Indicate which of their programs and drugs are available for
partnering
        and, optionally, what type of partnership they are seeking in which
        regions of the world.
    --  Add and update partnering contacts together with links to LinkedIn
        profiles.
    --  Display attendance at partnering conferences and increase networking
        opportunities.
    
</pre>
<p>"Pharma companies need new and innovative ways to share the financial risk of developing drugs," said <span class="xn-person">Mark Gordon</span>, director of product strategy at Thomson Reuters. "This new initiative benefits both drug innovators, who can easily update their partnering information online, as well as in-licensors, who can quickly find assets available for partnering."</p>
<p/>
<p>"The Outpartnering Registry from Thomson Reuters will make it easier for us to market products for our clients," said <span class="xn-person">Damon Bowe</span>, consultant at <span class="xn-location">New Orleans</span> BioInnovation Center. "The industry has expressed the need for this registry and it is an effective way for us to market inventions and to create partnerships between academia and industry."</p>
<pre>
    


    
</pre>
<p>For more information about The Outpartnering Registry, please visit: <a href="http://go.thomsonreuters.com/outpartnering">http://go.thomsonreuters.com/outpartnering</a></p>
<p/>
<p>For more information about Thomson Pharma Partnering, please visit: <a href="http://go.thomsonreuters.com/partnering">http://go.thomsonreuters.com/partnering</a></p>
<pre>
    

    Thomson Reuters
    
</pre>
<p>Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.  With headquarters in New York and major operations in <span class="xn-location">London</span> and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries.  For more information, go to <a href="http://www.thomsonreuters.com">www.thomsonreuters.com</a>.</p>
<pre>
    




    

For further information: Paul Sandell, Healthcare & Science, [phone], [email protected] Web Site: http://www.thomsonreuters.com